Ankylosing Spondylitis Treatment Market To Reach $5.6 Billion by 2035

Ankylosing spondylitis treatment market is witnessing steady growth, projected to expand from $6.5 billion in 2025 to $11.2 billion by 2035, registering a CAGR of 5.6% during the forecast period (2026–2035). The market is driven by the rising prevalence of chronic inflammatory diseases, increasing biologic drug adoption, and expanding access to advanced therapeutics across emerging economies. A key macro driver supporting this growth is the rising burden of musculoskeletal and autoimmune disorders globally. According to the World Health Organization (WHO), musculoskeletal conditions affect over 1.71 billion people worldwide, making them the leading contributor to disability. Ankylosing spondylitis (AS), a chronic inflammatory disease affecting the spine, is a significant subset of this burden. Furthermore, data from the U.S. Food and Drug Administration (FDA) indicate increasing approvals for biologic and targeted therapies in autoimmune diseases, accelerating treatment availability and innovation. This growing disease prevalence, combined with improved diagnostic rates, is directly translating into higher treatment demand, thereby strengthening the ankylosing spondylitis treatment market.

Browse the full report description of “Ankylosing Spondylitis Treatment Market Size, Share & Trends Analysis Report, By Drug Class (NSAIDs, Biologics, Targeted Synthetic DMARDs, Conventional Synthetic DMARDs, Corticosteroids), By Treatment Line (First-Line Therapy, Second-Line Therapy, Third-Line / Refractory Treatment), By End User (Hospitals, Specialty Clinics, Homecare Settings), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/ankylosing-spondylitis-treatment-market

Among segments, Biologics (TNF inhibitors and IL-17 inhibitors) represent the fastest-growing drug class due to superior efficacy in reducing inflammation and slowing disease progression compared to traditional NSAIDs. Increasing physician preference for biologics and expanding reimbursement coverage in developed regions are significantly boosting adoption rates. Market players are actively adopting strategic initiatives between 2022 and 2026 to strengthen their market presence and expand product portfolios:

• In May 2022, UCB announced Phase 3 results for Bimekizumab in psoriatic arthritis at the European Congress of Rheumatology (EULAR) 2022. The therapy demonstrated significant improvements in joint and skin symptoms, highlighting the growing importance of IL-17 pathway inhibitors, which are also being developed for Ankylosing Spondylitis and are expected to drive future market growth.

• In November 2024, UCB received U.S. FDA approval for BIMZELX for the treatment of hidradenitis suppurativa, marking its fifth indication. The therapy is already approved for Ankylosing Spondylitis, and this label expansion strengthens its commercial footprint and reinforces the growing importance of IL-17 pathway inhibitors in the ankylosing spondylitis treatment market.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Drug Class
  • By Treatment line
  • By End users
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape – AbbVie, Amgen, Pfizer, Novartis, Eli Lilly and Company, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Ankylosing Spondylitis Treatment Market Report Segment

By Drug Class

• NSAIDs
• Biologics
• Targeted Synthetic DMARDs (tsDMARDs)
• Conventional Synthetic DMARDs (csDMARDs)
• Corticosteroids

 By Treatment Line

• First-Line Therapy
• Second-Line Therapy
• Third-Line / Refractory Treatment

By End User

• Hospitals
• Specialty Clinics
• Homecare Settings

Global Ankylosing Spondylitis Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/ankylosing-spondylitis-treatment-market